Sarcoidosis exacerbation refers to acute worsening of a known sarcoidosis diagnosis, most commonly presenting with increased cough, dyspnea, chest pain, and fatigue. In patients with advanced pulmonary sarcoidosis, acute deterioration may result from worsening granulomatous inflammation, superimposed infection, acute bronchospasm, or extrapulmonary complications. [1] Approximately 73% of patients with sarcoidosis-associated pulmonary fibrosis report two or more acute worsening events per year. [1] The overall 5-year mortality rate for sarcoidosis is approximately 7%, with >60% of deaths attributable to advanced cardiopulmonary disease. [2-3]
1. History
- Key HPI questions: Onset, duration, and trajectory of worsening dyspnea, cough (productive vs. dry), chest pain, and exercise intolerance
- Symptom characterization: Cough is present in >90% of acute pulmonary exacerbations; dyspnea (29%) and chest pain (23%) are common baseline symptoms that may intensify [2][4]
- Timing/triggers: Recent medication changes (steroid taper, missed doses of immunosuppressants), recent infections, environmental/occupational exposures
- Associated symptoms: Fever, night sweats, weight loss, fatigue, palpitations, syncope, visual changes, skin lesions, joint pain
- Important negatives: Hemoptysis (consider superimposed infection, aspergilloma), orthopnea/PND (cardiac sarcoidosis or pulmonary hypertension), neurologic deficits (neurosarcoidosis)
- Medication adherence: Current steroid dose, immunosuppressant regimen, recent taper history [2][5]
2. Alarm Features
- Syncope, presyncope, or palpitations → cardiac sarcoidosis with arrhythmia or high-grade AV block [4][6]
- Sudden cardiac death risk — VT or unexplained cardiac arrest [6-7]
- Acute hypoxemic respiratory failure — severe dyspnea at rest, SpO₂ <90%
- New neurologic deficits — cranial nerve palsies (especially CN VII), seizures, altered mental status → neurosarcoidosis [5]
- Acute visual loss or eye pain → uveitis/optic neuritis requiring emergent ophthalmology evaluation [8]
- Hemoptysis — consider mycetoma/aspergilloma in fibrocystic disease or superimposed infection
- Hypercalcemic crisis — altered mental status, polyuria, dehydration, renal failure [8-9]
- Signs of pulmonary hypertension — progressive exertional dyspnea, RV failure, lower extremity edema [2-3]
3. Medications
- First-line treatment: Oral prednisone 20–40 mg/day for 2–6 weeks, then taper over 6–18 months. A recent RCT showed methotrexate has comparable efficacy to prednisone as first-line therapy with a different side-effect profile [2][10]
- Second-line (steroid-sparing): Methotrexate 5–25 mg/week (with folic acid), azathioprine 50–200 mg/day, mycophenolate mofetil 500–3000 mg/day, leflunomide 10–20 mg/day [2][5]
- Third-line: Infliximab 3–5 mg/kg IV at 0, 2 weeks, then every 4–8 weeks; adalimumab 40 mg SC every 1–2 weeks [2]
- Hydroxychloroquine — useful for cutaneous disease, hypercalcemia, and some neurosarcoidosis [5]
- Löfgren syndrome: NSAIDs are first-line [2]
- Pulmonary hypertension: PDE-5 inhibitors, prostacyclin analogues [2]
- Contraindicated/cautions: Anti-TNF agents increase risk of acute worsening events in patients with bronchiectasis; patients on combined immunosuppression require Pneumocystis jirovecii and herpes zoster prophylaxis [1-2]
- Medication contributors to flare: Immune checkpoint inhibitors, interferon, and paradoxically anti-TNF agents can cause sarcoid-like reactions [2][9]
The following table summarizes the treatment ladder:
4. Diet
- Hypercalcemia management: Limit calcium and vitamin D supplementation; avoid excessive dairy intake in patients with active granulomatous disease producing 1,25-dihydroxyvitamin D [8]
- Hydration: Aggressive IV/oral hydration if hypercalcemic
- Steroid-related considerations: Counsel on weight management, sodium restriction, and glucose monitoring given prednisone-associated weight gain (mean +5 kg at 24 weeks) and metabolic effects [10]
- Methotrexate: Avoid alcohol due to hepatotoxicity risk
5. Review of Systems
- Pulmonary: Cough, dyspnea, wheezing, hemoptysis, chest tightness
- Cardiac: Palpitations, syncope, presyncope, exertional dyspnea, orthopnea, lower extremity edema [4][6]
- Neurologic: Headache, facial weakness/numbness, seizures, cognitive changes, neuropathic pain [5][8]
- Ophthalmologic: Eye pain, redness, blurred vision, photophobia [8]
- Dermatologic: New skin lesions (papules, plaques, erythema nodosum, lupus pernio) [8-9]
- Musculoskeletal: Arthralgias, myalgias, proximal weakness [8]
- Renal: Polyuria, polydipsia, flank pain (nephrolithiasis/nephrocalcinosis) [8]
- Constitutional: Fever, night sweats, weight loss, profound fatigue [5][8]
- GI/Hepatic: Abdominal pain, hepatomegaly symptoms [8]
6. Collateral History and Family History
- Collateral: Confirm medication adherence, recent steroid taper, functional baseline, prior exacerbation frequency and triggers
- Family history: Sarcoidosis has a strong hereditary component associated with the HLA region on chromosome 6; familial clustering is well-documented. First-degree relatives of affected individuals have a 4–5× increased risk [7]
- Social context: Occupational exposures (beryllium, silica, mold), smoking status, insurance/access barriers to immunosuppressive therapy, psychosocial impact of chronic disease [5]
7. Risk Factors
- Demographic: Age 25–45 years (peak onset), Black race (higher incidence, severity, and mortality — 2.4× higher mortality in Black women), female sex [5][9]
- Adverse prognostic factors: Age ≥40 at onset, Scadding stage III–IV, lupus pernio, chronic uveitis, cardiac/neurologic/renal involvement, hypercalcemia, pulmonary hypertension [5]
- Triggers for exacerbation: Steroid taper or discontinuation (45% relapse rate within 12–18 months of stopping prednisone), superimposed infection, bronchiectasis, anti-TNF therapy [1][10]
- Genetic: HLA-DRB114, HLA-DRB115 (adverse); HLA-DRB103 (favorable/Löfgren) [5]
8. Differential Diagnosis
In a patient with known sarcoidosis presenting with acute worsening, the critical question is whether the deterioration represents a true sarcoidosis flare vs. an alternative or superimposed process:
- Superimposed infection (most important to exclude) — bacterial pneumonia, opportunistic infections (PJP, fungal) in immunosuppressed patients, aspergilloma in fibrocystic disease [1-2]
- Pulmonary embolism — especially in patients with reduced mobility or active inflammation
- Cardiac sarcoidosis — new arrhythmia, heart block, or heart failure mimicking pulmonary exacerbation [6]
- Sarcoidosis-associated pulmonary hypertension — progressive dyspnea out of proportion to parenchymal disease [2-3]
- Drug-induced pneumonitis — methotrexate pneumonitis [2]
- Lymphoma — can coexist with or mimic sarcoidosis; consider if B symptoms present [2]
- Tuberculosis/NTM — especially in endemic areas or immunosuppressed patients [2][9]
- Hypersensitivity pneumonitis — new environmental exposure [2][11]
- Heart failure from other causes — steroid-induced cardiomyopathy, ischemic disease
9. Past Medical History
- Prior sarcoidosis course: Scadding stage at diagnosis, organs involved, prior exacerbation frequency, prior biopsy results
- Treatment history: Cumulative steroid exposure, prior steroid-sparing agents used, treatment failures, adverse drug reactions
- Comorbidities: Diabetes (steroid-induced), osteoporosis, cataracts, glaucoma, hypertension — all steroid-related complications [10]
- Surgical history: Prior lung biopsy, cardiac device implantation (ICD/pacemaker for cardiac sarcoidosis)
- Screening history: Last ophthalmologic exam, last ECG/echocardiogram, last PFTs
10. Physical Exam
- Vitals: Tachypnea, hypoxia (SpO₂), tachycardia, fever (infection vs. active sarcoidosis), blood pressure (hypercalcemia-related hypertension)
- Pulmonary: Crackles (parenchymal disease), wheezing (endobronchial sarcoidosis/bronchospasm), decreased breath sounds (effusion, fibrosis)
- Cardiac: Irregular rhythm (arrhythmia), new murmur, S3 (heart failure), JVD, peripheral edema (RV failure/pulmonary hypertension) [4][6]
- Skin: Erythema nodosum, lupus pernio (violaceous plaques on nose/cheeks — pathognomonic), papules, plaques, subcutaneous nodules [8-9]
- Eyes: Conjunctival injection, photophobia (uveitis)
- Neurologic: Cranial nerve palsies (especially CN VII), peripheral neuropathy, proximal weakness
- Lymph nodes: Peripheral lymphadenopathy (cervical, axillary, inguinal)
- Abdomen: Hepatosplenomegaly [8]
- MSK: Joint swelling (especially ankles in Löfgren syndrome)
11. Lab Studies
- Baseline labs: CBC with differential (lymphopenia common), BMP (calcium — hypercalcemia in 3–12%), renal function, LFTs (transaminitis with hepatic involvement), urinalysis [8]
- Inflammatory markers: ESR, CRP — nonspecific but useful for trending
- ACE level: Elevated in 50–60% but lacks specificity; more useful for monitoring treatment response than diagnosis [5][8]
- Calcium metabolism: Serum calcium, 25-OH vitamin D, 1,25-dihydroxyvitamin D, PTH (to evaluate granulomatous hypercalcemia) [9]
- Infection workup: Blood cultures, sputum cultures (bacterial, AFB, fungal), procalcitonin, beta-D-glucan, galactomannan if immunosuppressed
- Additional: Soluble IL-2 receptor (sIL-2R) — useful for assessing disease activity; 24-hour urine calcium if hypercalciuria suspected [5][8]
- Monitoring on immunosuppressants: CBC, LFTs (methotrexate hepatotoxicity in ~25%), renal function [10]
12. Imaging
- First-line: Chest X-ray — bilateral hilar lymphadenopathy (50–85%), parenchymal opacities (20–65%); Scadding staging remains the oldest prognostic biomarker [4]
- HRCT chest: Superior for detecting parenchymal detail — perilymphatic nodules along bronchovascular bundles, ground-glass opacities (active inflammation), fibrocystic changes, traction bronchiectasis, conglomerate masses [4]
- When to image: Compare to prior imaging to assess progression; new ground-glass opacities suggest active inflammation amenable to steroids, while fibrotic changes (honeycombing, architectural distortion) suggest irreversible disease [2]
- FDG-PET/CT: Most effective for detecting tissue-specific inflammatory activity; useful in refractory disease, identifying biopsy sites, and monitoring treatment response [4-5]
- Cardiac MRI: Gold standard for cardiac sarcoidosis — late gadolinium enhancement (LGE) identifies myocardial fibrosis/inflammation [6][12]
- Brain MRI with gadolinium: If neurosarcoidosis suspected [5]
13. Special Tests
- Pulmonary function tests: Spirometry (restrictive, obstructive, or mixed pattern), DLCO (often reduced) — essential for monitoring disease progression and treatment response; repeat every 3–12 months [2][4]
- Scadding staging system (CXR-based): [3-4]
- Stage 0: Normal CXR
- Stage I: Bilateral hilar lymphadenopathy (BHL) alone
- Stage II: BHL + pulmonary infiltrates
- Stage III: Pulmonary infiltrates without BHL
- Stage IV: Pulmonary fibrosis
- Bronchoscopy with BAL: Lymphocytosis (~90% at diagnosis), CD4:CD8 ratio >3–4 has >95% specificity in some studies; also useful to exclude infection [4]
- Transbronchial biopsy / EBUS-TBNA: Sensitivity ≥80% for pulmonary sarcoidosis; indicated if diagnosis uncertain or infection needs exclusion [2]
- 6-minute walk test: Assess functional capacity and oxygen desaturation
- Right heart catheterization: If pulmonary hypertension suspected [2][8]
14. ECG
- Indications: Baseline ECG recommended for all sarcoidosis patients; repeat with any cardiac symptoms [6]
- Key findings:
- High-grade AV block (most common cardiac sarcoidosis manifestation — up to 42%) [4][12]
- Bundle branch blocks (especially RBBB)
- Ventricular tachycardia (monomorphic or polymorphic)
- Atrial fibrillation/flutter (up to 32%) [4]
- Nonspecific ST-T wave changes
- Red flag patterns: New AV block in a patient <60 years, unexplained VT, or new bundle branch block should prompt urgent evaluation for cardiac sarcoidosis [6]
- Additional monitoring: Holter monitor or event recorder if palpitations, syncope, or presyncope reported [8]
15. Assessment
- Severity stratification: Based on degree of respiratory impairment (SpO₂, PFTs), Scadding stage, number of organs involved, and presence of high-risk organ involvement (cardiac, neurologic, renal) [5]
- Typical exacerbation: Worsening cough and dyspnea with new or progressive infiltrates on imaging, often triggered by steroid taper; responds to increased corticosteroid dosing or antibiotics if infection-related [1]
- Atypical presentations to consider: Isolated cardiac symptoms (syncope, palpitations), neurologic deficits, hypercalcemic crisis, acute renal failure
- Complications: Progressive pulmonary fibrosis (stage IV), pulmonary hypertension (up to 70% in advanced disease with ~40% 5-year mortality), aspergilloma, respiratory failure, sudden cardiac death [2-3]
- Relapse rates: 13–75% depending on stage, number of organs involved, and population studied; 45% relapse within 12–18 months of stopping prednisone [3][10]
16. Treatment Plan
Initial stabilization (ED)
- Supplemental oxygen to maintain SpO₂ >92%
- IV access, continuous monitoring if hemodynamically unstable or arrhythmia suspected
- Treat hypercalcemia if present: IV normal saline bolus, consider calcitonin or bisphosphonates
Pharmacologic management
- Acute flare: Increase or restart prednisone 20–40 mg/day for 2–6 weeks, then taper based on clinical/radiographic response over 6–18 months [2]
- Steroid-refractory or steroid-dependent (unable to taper below 10 mg/day): Add methotrexate 5–25 mg/week or azathioprine 50–200 mg/day [2][5]
- Third-line: Infliximab for refractory disease [2]
- Infection-triggered exacerbation: Appropriate antibiotics; ensure cultures obtained before escalating immunosuppression [1]
- Cardiac sarcoidosis: Corticosteroids for active inflammation; ICD for VT/VF or high-grade AV block; pacemaker for symptomatic bradycardia [6][13]
- Pulmonary hypertension: PDE-5 inhibitors, prostacyclin analogues [2]
- Prophylaxis on combined immunosuppression: TMP-SMX for PJP, consider antiviral for herpes zoster [2]
The following figure outlines the proposed treatment algorithm:
17. Disposition
Admission criteria
- Hypoxemic respiratory failure or significant oxygen requirement
- Hemodynamic instability
- New arrhythmia, high-grade AV block, or suspected cardiac sarcoidosis [6]
- Acute neurologic deficits (neurosarcoidosis)
- Symptomatic hypercalcemia or acute kidney injury
- Severe exacerbation requiring IV medications or close monitoring
- Inability to exclude serious superimposed infection in immunosuppressed patient
Observation indications
- Moderate exacerbation with borderline oxygen requirement
- Pending workup for infection vs. flare distinction
Discharge criteria
- Mild exacerbation with stable vitals, adequate oxygenation on room air
- Able to tolerate oral medications
- Reliable follow-up arranged with pulmonology within 1–2 weeks
- No evidence of high-risk organ involvement (cardiac, neurologic)
Specialist consultation triggers
- Pulmonology: All exacerbations requiring treatment escalation
- Cardiology: Any cardiac symptoms, ECG abnormalities, or suspected cardiac sarcoidosis [6]
- Ophthalmology: Visual symptoms or known uveitis
- Neurology: New neurologic deficits [5]
- Rheumatology: Refractory multisystem disease
- Transplant evaluation: Stage IV with progressive respiratory failure or refractory cardiac sarcoidosis [8][14]
18. Follow Up / Return Precautions
- Follow-up timing: Pulmonology within 1–2 weeks for mild-moderate exacerbations; sooner if steroid dose escalated or new immunosuppressant started
- Monitoring schedule: Repeat spirometry, DLCO, and chest imaging every 3–12 months depending on severity [2]
- Symptoms requiring immediate reassessment:
- Worsening shortness of breath or new oxygen requirement
- Syncope, palpitations, or chest pain (cardiac sarcoidosis)
- New facial weakness, seizures, or vision changes
- Fever or productive cough (superimposed infection)
- Confusion, excessive thirst/urination (hypercalcemia)
- Patient counseling:
- Do not abruptly stop corticosteroids — taper must be supervised
- Report signs of infection promptly (immunosuppression risk)
- Annual ophthalmologic examination recommended [8]
- Bone density monitoring and calcium/vitamin D management per steroid exposure
- Expected recovery: Oral glucocorticoids typically improve radiographic infiltrates within 4–12 weeks; however, relapse is common (up to 45% within 12–18 months of stopping therapy), and many patients require prolonged or indefinite treatment [2][10]
References
1. Pulmonary Sarcoidosis. — Spagnolo P, Rossi G, Trisolini R, et al. The Lancet. Respiratory Medicine. 2018.
2. Diagnosis and Treatment of Pulmonary Sarcoidosis: A Review. — Belperio JA, Shaikh F, Abtin FG, et al. The Journal of the American Medical Association. 2022.
3. Pulmonary Sarcoidosis: A Comprehensive Review: Past to Present. — Belperio JA, Fishbein MC, Abtin F, et al. Journal of Autoimmunity. 2024.
4. Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review. — Trivieri MG, Spagnolo P, Birnie D, et al. Journal of the American College of Cardiology. 2020.
5. Challenges of Sarcoidosis and Its Management. — Drent M, Crouser ED, Grunewald J. The New England Journal of Medicine. 2021.
6. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. — Cheng RK, Kittleson MM, Beavers CJ, et al. Circulation. 2024.
7. Cardiovascular Manifestations and Immunobiology of Sarcoidosis. — Weintraub NL, Guha A, Taskar V, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025.
8. Sarcoidosis: Evaluation and Treatment. — Partin M, Clebak KT, Chen R, Helm M. American Family Physician. 2024.
9. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. — Crouser ED, Maier LA, Wilson KC, et al. American Journal of Respiratory and Critical Care Medicine. 2020.
10. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. — Kahlmann V, Janssen Bonás M, Moor CC, et al. The New England Journal of Medicine. 2025.
11. Differential Diagnosis of Pulmonary Sarcoidosis: A Review. — Valeyre D, Brauner M, Bernaudin JF, et al. Frontiers in Medicine. 2023.
12. Novel Imaging Approaches To Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement. — Weber BN, Paik JJ, Aghayev A, et al. Journal of the American College of Cardiology. 2023.
13. Cardiac Sarcoidosis: Phenotypes, Diagnosis, Treatment, and Prognosis. — Lehtonen J, Uusitalo V, Pöyhönen P, Mäyränpää MI, Kupari M. European Heart Journal. 2023.
14. Sarcoidosis. — Cooper D, Suau S. Immunology and Allergy Clinics of North America. 2023.